Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on February 7, 2013. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The Board of Directors increased its size from six to seven directors, effective December 18, 2012. On February 7, 2013, Thomas C. Reynolds, M.D., Ph.D., was appointed to fill the resulting vacancy. This appointment was proposed pursuant to governance agreements entered into on December 18, 2012, with Vivo Ventures Fund VII, L.P. and New Leaf Ventures II, L.P.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Dr. Reynolds will receive standard compensation for non-employee directors and will enter into the company's standard indemnification agreement, details of which are referenced in the Schedule 14A proxy statement filed on October 28, 2011.
Investor Verification Checklist
- Verify the details of the governance agreements with Vivo Ventures Fund VII, L.P. and New Leaf Ventures II, L.P. dated December 18, 2012.
- Review the definitive proxy statement on Schedule 14A (filed October 28, 2011) for specific compensation and indemnification terms for non-employee directors.
- Confirm the press release dated February 11, 2013 (Exhibit 99.1) for additional context on Dr. Reynolds' background.